Arcutis sets director cash retainers at $50k-$35k, annual equity value at $300k; all proposals at annual meeting pass

Arcutis Biotherapeutics, Inc.

Cash retainers: $50k for non-employee directors; additional $35k for non-exec chair; committee chairs $20k (audit), $15k (comp), $10k (nominating).
Equity: initial option up to $300k value for new directors; annual award ~$300k split 65% option (up to $195k) and 35% RSU (up to $105k).
Plan amended effective June 11, 2025; board approved revisions to attract and retain qualified directors.
Shareholders reelected directors Chaudhuri, Lin, Welgus; ratified Ernst & Young as auditor; approved non-binding say-on-pay.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.